Business Economy


CIL and AM Green aim for India’s largest RE Supply Contract

Hyderabad, May 9 (UNI) Coal India Limited (CIL), plans to supply 4,500 MW of carbon-free energy, in phased manner, to upcoming green ammonia facilities of AM Green.
It would be through a combination of solar and wind whose capacities CIL aims to set up on pan India basis.
This initiative aligns with India’s national goal of achieving a cleaner energy mix and transition towards net-zero emissions, the company said in a release on Friday.

A formal non-binding memorandum of understanding (MoU), for long-term supply and sourcing of renewable energy, was inked on Wednesday between the two entities.

While the solar power capacity would be to the tune of 2500 MW to 3000 MW, wind is expected to account between 1500 MW and 2000 MW at an estimated total outlay of around Rs. 25,000 Crores.
Potential sites for wind projects will be explored in the southern states of the country while for solar plants in the sunny states like Gujarat and Rajasthan.
AM Green will integrate the two renewable sources supplied by CIL with pumped hydro storage to ensure a steady supply of green energy to AM Green facilities.
“While coal remains our mainstay in meeting India’s expanding energy needs in the near term, our plans include a proactive role in building a greener and more sustainable future. This is in consonance with our commitment to become the country's integrated energy provider” said P M Prasad, CIL’s Chairman.
AM Green, promoted by the founders of Greenko, one of India’s leading energy transition solutions providers, targets to produce 5 million tons per annum (MTPA) of green ammonia by 2030. This equals around 1 MTPA of green hydrogen and represents a fifth of India’s target for green hydrogen production under the National Green Hydrogen Mission.
Anil Chalamalasetty, Founder of the Hyderabad based Greenko Group & AM Green, said, “We aim to become one of the most cost-competitive producers of green hydrogen, green ammonia, and other green molecules in the world”.
The agreement was signed by Sudarsan Bora, GM (E&M) representing CIL while his counterpart from AM Green was Shatanshu Agrawal, Sr. Vice President – Business Development.
P M Prasad, Chairman, CIL, Mukesh Choudhary, Director (Marketing) CIL and Anil Kumar, GM (MM & Solar) CIL were also present.
UNI KNR RN
More News

RBI’s rate cut sets pro-growth tone as Inflation outlook softens sharply: SBI

06 Dec 2025 | 8:23 PM

New Delhi, Dec 6 (UNI) The Reserve Bank of India’s latest move to cut the repo rate by 25 basis points to 5.25 per cent reflects a clear commitment to support growth at a time when inflation is easing sharply and global uncertainties are rising, SBI said in its Ecowrap report.

see more..

India should launch National Satellite Connectivity Mission: SIA-India

06 Dec 2025 | 3:47 PM

Chennai, Dec 6 (UNI) Space Industry Association of India (SIA-India) SIA-India has called for the launch of a National Satellite Connectivity Mission (NSCM) to ensure uninterrupted digital governance and public service continuity in about 40,000 Gram Panchayats where terrestrial links repeatedly fail due to topographical challenges, multi-week outage cycles, and chronic disaster exposure. .

see more..

PHDCCI proposes direct tax reforms to drive investment and ease of doing business

06 Dec 2025 | 2:45 PM

New Delhi, Dec 6 (UNI) The PHD Chamber of Commerce and Industry (PHDCCI) has put forward an extensive set of recommendations to the government, calling for a major overhaul of India’s direct tax framework.

see more..

Netflix announces deal to buy Warner Bros & HBO

06 Dec 2025 | 3:45 AM

California, Dec 5 (UNI) In a major development in media industry, Netflix has triumphed in the bidding war for Warner Bros. and HBO, announcing a deal that could combine two of the three biggest streamers with one of the largest traditional movie and television studios.

see more..

Lupin gets US FDA approval for multiple sclerosis tablet

05 Dec 2025 | 8:43 PM

Chennai, Dec 5 (UNI) Pharmaceutical major Lupin Ltd on Friday announced that it has received tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Siponimod Tablets, 0.25 mg, 1 mg, and 2 mg.
This product would be manufactured at Lupin’s Pithampur facility in India.

see more..